CODX Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
282.9K
+70.3%
166.1K
+13.8%
146.0K
-44.7%
263.9K
+81.5%
145.4K
Cost of Revenue
303.3K
+569.6%
45.3K
-76.6%
193.8K
+36.1%
142.4K
+441.7%
26.3K
Gross Profit
-20463
-116.9%
120.8K
+352.7%
-47814
-139.3%
121.5K
+2.0%
119.1K
Operating Expenses
6.2M
-1.2%
6.3M
-31.0%
9.2M
-65.6%
26.7M
+273.8%
7.1M
R&D
3.6M
-13.9%
4.2M
-30.0%
5.9M
+16.4%
5.1M
+13.8%
4.5M
SG&A
2.5M
+24.6%
2.0M
-33.8%
3.0M
+23.0%
2.4M
+1.2%
2.4M
Operating Income
-6269350
-1.1%
-6200783
+32.7%
-9208411
+65.3%
-26541784
-278.4%
-7013848
EBITDA
-6046987
-0.8%
-5998943
+33.0%
-8952966
-21.1%
-7392218
-9.6%
-6746465
Net Income
-6306408
-0.4%
-6283786
+31.2%
-9140038
+64.5%
-25745725
-337.3%
-5886823
EPS (Basic)
$-1.01
+30.8%
$-1.46
+64.0%
$-4.06
+70.3%
$-13.65
-192.9%
$-4.66
EPS (Diluted)
$-1.01
+30.8%
$-1.46
+64.0%
$-4.06
+70.3%
$-13.65
-192.9%
$-4.66
Shares (Diluted)
6.3M
+45.5%
4.3M
+91.3%
2.3M
+19.5%
1.9M
+49.3%
1.3M
Co-Diagnostics (CODX) — Financials